Novo Nordisk reported Phase 3 FRONTIER2 results showing denecimig reduced bleeding rates by up to 99% in haemophilia A; findings published in the New England Journal of Medicine.
Written By: Sana Khan, BPharm
Reviewed By: Pharmacally Editorial Team
Novo Nordisk reported 26-week results from the Phase 3 FRONTIER2 trial evaluating denecimig (Mim8), an investigational prophylactic therapy for haemophilia A in adults and adolescents aged 12 years and older, with or without Factor VIII inhibitors. The data have been published in the New England Journal of Medicine.
Denecimig is a bispecific antibody that mimics activated Factor VIII (FVIIIa), designed to restore thrombin generation and support blood clot formation. The therapy is administered subcutaneously and is being studied across multiple dosing regimens within the broader FRONTIER clinical program.
The FRONTIER2 trial (NCT05053139) enrolled 254 participants and compared once-monthly and once-weekly denecimig with prior prophylactic clotting factor therapy or on-demand treatment. The primary endpoint assessed annualized bleeding rates (ABR) requiring treatment.
Results showed substantial reductions in bleeding episodes with both dosing regimens. Patients receiving once-monthly denecimig experienced approximately 99% fewer treated bleeds compared with on-demand therapy and about 43% fewer compared with prior prophylaxis. Those on once-weekly dosing showed around 96% fewer bleeds versus on-demand treatment and a 54% reduction compared with prior prophylaxis.
Across study arms, zero treated bleeds were reported in 64% to 95% of participants receiving denecimig. In contrast, zero treated bleeds were observed in 0% to 37% of participants in comparator groups, depending on prior treatment exposure.
Safety findings indicated that denecimig was generally well tolerated. No thromboembolic events or neutralising anti-drug antibodies were reported. Injection-site reactions occurred in 10% of participants and were associated with 2.6% of injections.
The trial’s lead investigator, Maria Elisa Mancuso, noted that reducing bleeding episodes remains a central goal in haemophilia A management and that these findings support denecimig’s potential across different disease severities and inhibitor statuses.
Anna Windle, Head of Clinical Development, Medical & Regulatory Affairs at Novo Nordisk US Operations stated that the observed reductions in bleeding rates highlight the therapy’s potential to address ongoing unmet needs while reducing treatment burden.
Denecimig remains investigational and has not yet received regulatory approval. Novo Nordisk submitted a Biologics License Application to the U.S. FDA in September 2025 for its evaluation.
Haemophilia A is a rare inherited bleeding disorder caused by deficient or defective Factor VIII, affecting an estimated 836,000 people globally. Approximately 30% of patients develop inhibitors that reduce the effectiveness of replacement therapies, highlighting the need for alternative treatment approaches.
References
Novo Nordisk A/S: Denecimig (Mim8) significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM, 30 April 2026, News Details